HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price

Plus Therapeutics (NASDAQ:PSTV) had its price objective lowered by analysts at HC Wainwright from $8.00 to $5.50 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 374.14% from the company’s current price. HC Wainwright also issued estimates for Plus Therapeutics’ FY2029 earnings at $0.95 EPS.

PSTV has been the subject of a number of other reports. Ascendiant Capital Markets decreased their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th. D. Boral Capital began coverage on Plus Therapeutics in a research note on Monday, March 17th. They set a “buy” rating and a $9.00 price target for the company.

Plus Therapeutics Price Performance

Shares of PSTV stock opened at $1.16 on Friday. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67. The stock’s 50-day moving average is $1.11 and its two-hundred day moving average is $1.24. The firm has a market cap of $6.84 million, a P/E ratio of -0.46 and a beta of 0.73.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $1.19 million. As a group, research analysts expect that Plus Therapeutics will post -2.3 EPS for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.